Jason Laday

1 month ago | healio.com | Jason Laday

Read more The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, including those under rheumatology umbrella. However, while GLP-1 receptor agonists may eventually play a role — perhaps even a significant one — in the specialty, more information is needed to more concretely determine its benefits.

1 month ago | healio.com | Jason Laday

Key takeaways: The FDA has approved upadacitinib to treat adults with giant cell arteritis. It is the second drug to be specifically approved for the disease in the United States after tocilizumab in 2017. The FDA has approved the Janus kinase inhibitor upadacitinib for the treatment of giant cell arteritis in adults, the first such approval in the disease since tocilizumab received the green light in 2017, according to a press release.

1 month ago | healio.com | Leonard Calabrese |Jason Laday

In this Healio video exclusive, Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, highlighted recent coverage of the rise in physician union membership, as well as Congress’s latest stopgap funding measure. “It’s really quite varied and it’s really on some of the business, funding, intellectual aspects of our profession,” Calabrese said. “Unionization — plusses and minuses.

Oct 30, 2024 | healio.com | Jason Laday |Shenaz Bagha

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA has expanded the approval of an oral liquid methotrexate solution to include children and adolescents with polyarticular juvenile idiopathic arthritis and acute lymphoblastic leukemia, according to a press release.

Sep 23, 2024 | healio.com | Jason Laday |Shenaz Bagha |Emmanuel Caeymaex |Joseph F. Merola

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The FDA has approved bimekizumab-bkzx for three new indications — PsA, AS and non-radiographic axial SpA. The approvals come in the wake of four phase 3 studies.